S A Rosenberg

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Raising the bar: the curative potential of human cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 4:127ps8. 2012
  2. ncbi The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
  3. ncbi Overcoming obstacles to the effective immunotherapy of human cancer
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:12643-4. 2008
  4. ncbi Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 8:299-308. 2008
  5. ncbi Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:6169-76. 2005
  6. ncbi Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
    S A Rosenberg
    Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 163:1690-5. 1999
  7. ncbi IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
  8. ncbi Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 29:224-31. 2006
  9. ncbi Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy
    Steven A Rosenberg
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
    J Immunol 168:2402-7. 2002
  10. ncbi Progress in the development of immunotherapy for the treatment of patients with cancer
    S A Rosenberg
    National Cancer Institute, Institutes of Health, Bethesda, MD 20892, USA
    J Intern Med 250:462-75. 2001

Detail Information

Publications136 found, 100 shown here

  1. ncbi Raising the bar: the curative potential of human cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Sci Transl Med 4:127ps8. 2012
    ..Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers...
  2. ncbi The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
    Sid P Kerkar
    Surgery Branch, CCR, NCI, Bethesda, MD, USA
    Trials 10:121. 2009
    ..Surgeries and followup will be done at the NCI, and chemotherapy will be given by either the local oncologist or the medical oncology branch at NCI. TRIAL REGISTRATION: ClinicalTrials.gov ID. NCT00941655...
  3. ncbi Overcoming obstacles to the effective immunotherapy of human cancer
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 105:12643-4. 2008
  4. ncbi Adoptive cell transfer: a clinical path to effective cancer immunotherapy
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 8:299-308. 2008
    ....
  5. ncbi Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:6169-76. 2005
    ..Further, the induction of even high levels of antitumor T cells may be insufficient to alter tumor progression...
  6. ncbi Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
    S A Rosenberg
    Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 163:1690-5. 1999
    ..These represent the first detailed studies of the impact of immunization with tumor peptides in conjunction with a variety of cytokines in patients with metastatic cancer...
  7. ncbi IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 29:313-9. 2006
    ..These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia...
  8. ncbi Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 29:224-31. 2006
    ....
  9. ncbi Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy
    Steven A Rosenberg
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892, USA
    J Immunol 168:2402-7. 2002
    ..Overexpression was not found in normal tissues or other tumor types. Thus, BING-4 represents another candidate Ag for possible use in the immunotherapy of patients with melanoma...
  10. ncbi Progress in the development of immunotherapy for the treatment of patients with cancer
    S A Rosenberg
    National Cancer Institute, Institutes of Health, Bethesda, MD 20892, USA
    J Intern Med 250:462-75. 2001
    ....
  11. ncbi Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Proc Natl Acad Sci U S A 101:14639-45. 2004
    ..These studies are elucidating the requirements for successful immunotherapy of patients with advanced metastatic disease and are leading to additional clinical trials with gene-modified lymphocytes...
  12. ncbi Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1502, USA
    Hum Gene Ther 14:709-14. 2003
    ..We were thus unable to demonstrate significant clinical or immunologic responses to plasmid DNA encoding the "self" nonmutated gp100 tumor antigen...
  13. ncbi Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma
    Steven A Rosenberg
    Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA
    J Immunother 26:385-93. 2003
    ....
  14. ncbi Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:4550-7. 2011
    ..We investigated the ability of adoptive cell transfer utilizing autologous tumor-infiltrating lymphocytes (TIL) to mediate durable complete regressions in heavily pretreated patients with metastatic melanoma...
  15. ncbi Adoptive cell therapy for the treatment of patients with metastatic melanoma
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    Curr Opin Immunol 21:233-40. 2009
    ..We recently demonstrated that ACT using autologous lymphocytes genetically modified to express anti-tumor T cell receptors can mediate tumor regression and this approach is now being applied to patients with common epithelial cancers...
  16. ncbi Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know
    Steven A Rosenberg
    Surgery Branch, National Cancer Institute, National Institutes of Health, CRC Building 10, Room 3 3940, 10 Center Drive, Bethesda, MD 20892 1201, USA
    Nat Rev Clin Oncol 8:577-85. 2011
    ..This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer...
  17. ncbi Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine
    Steven A Rosenberg
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 1201, USA
    J Immunother 33:626-9. 2010
    ..A survey of ongoing clinical trials listed in ClinicalTrials.gov revealed 36 trials currently accruing patients that are using the olive-derived Montanide ISA 51 IFA...
  18. ncbi Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition
    S Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Gene Ther 15:1411-23. 2008
    ..Such optimal vectors may have immediate applications in cancer gene therapy...
  19. ncbi Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
    Giao Q Phan
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 100:8372-7. 2003
    ..This study establishes CTLA-4 as an important molecule regulating tolerance to "self" antigens in humans and suggests a role for CTLA-4 blockade in breaking tolerance to human cancer antigens for cancer immunotherapy...
  20. ncbi Kinetics of TCR use in response to repeated epitope-specific immunization
    V Monsurro
    HLA Laboratory, Department of Transfusion Medicine, Clinical Center, and Surgery Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 166:5817-25. 2001
    ..Thus, repeated exposure to immunogenic peptides benefited immune competence. These results provide a rationale for immunization strategies...
  21. ncbi Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:3515-9. 1994
    ..Identification of this gene opens possibilities for the development of immunotherapies for patients with melanoma...
  22. ncbi Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Science 284:1351-4. 1999
    ....
  23. ncbi Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 160:890-7. 1998
    ..However, peptide titration experiments showed that the affinity of TCR receptor to peptide/A33 could be higher than that to the peptide/A31. These studies have important implications for the development of peptide-based cancer vaccines...
  24. ncbi Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:3519-25. 1998
    ....
  25. ncbi Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells
    V Bronte
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 161:5313-20. 1998
    ..Finally, our results may shed new light on a mechanism for the suppression of CD8+ T cell responses and its effect on vaccine efficacy and on immune memory...
  26. ncbi Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution
    S Bownds
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:1-9. 2001
    ..1+ NY-ESO-1+ tumor cells, suggesting that this peptide may be clinically valuable for the treatment of patients with NY-ESO-1+ tumors...
  27. ncbi A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames
    R F Wang
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 161:3598-606. 1998
    ..Understanding of this mechanism by which the alternative reading frame is translated may have important implications in tumor immunology...
  28. ncbi Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase
    Timothy L Frankel
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 184:5988-98. 2010
    ..These results suggest that this highly active tyrosinase-specific TCR could be of value in adoptive cell transfer for melanoma...
  29. ncbi Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
    Ajay V Maker
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA
    J Immunol 175:7746-54. 2005
    ..Therefore, our results suggest that the antitumor effects of CTLA-4 blockade are due to increased T cell activation rather than inhibition or depletion of T regulatory cells...
  30. ncbi Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens
    Giao Q Phan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD 20892-1502, USA
    J Immunother (1997) 26:349-56. 2003
    ..Moreover, the sequential, nonrandomized nature of patient enrollment for the two trials may account for the differences in immunologic response...
  31. ncbi Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells
    Willem W Overwijk
    National Cancer Institute (NCI, National Institute of Health, Bethesda, MD 20892-1502, USA
    J Exp Med 198:569-80. 2003
    ....
  32. ncbi Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother (1997) 28:53-62. 2005
    ....
  33. ncbi Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
    Mark E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20902, USA
    Science 298:850-4. 2002
    ..This approach presents new possibilities for the treatment of patients with cancer as well as patients with human immunodeficiency virus-related acquired immunodeficiency syndrome and other infectious diseases...
  34. ncbi Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
    Y Kawakami
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
    Proc Natl Acad Sci U S A 91:6458-62. 1994
    ....
  35. ncbi Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma
    M E Dudley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother 24:363-73. 2001
    ..The lack of clinical effectiveness of this protocol suggests that transfer of different or additional cell types or that modulation of the recipient host environment is required for successful therapy...
  36. ncbi Human tumor antigens for cancer vaccine development
    R F Wang
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA
    Immunol Rev 170:85-100. 1999
    ..This review will summarize the current status of MHC class I- and class II-restricted human tumor antigens, and their potential application to cancer treatment...
  37. ncbi Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
    S A Rosenberg
    Surgery Branch and Department of Biostatistics and Data Management Section, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 17:968-75. 1999
    ..We have performed a prospective randomized trial in patients with metastatic melanoma, comparing treatment with chemotherapy to treatment with chemoimmunotherapy...
  38. ncbi Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1201, USA
    J Immunother (1997) 28:403-11. 2005
    ....
  39. ncbi Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors
    Michal Lotem
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunother (1997) 29:616-27. 2006
    ..These data suggest that DCs transduced with viral vectors may be more efficient than DCs transfected with cDNAs or RNAs for the induction of tumor reactive CD8+ and CD4+ T cells in vitro and in human vaccination trials...
  40. ncbi Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy
    Hung T Khong
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 168:951-6. 2002
    ....
  41. ncbi Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
    Marybeth S Hughes
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 16:457-72. 2005
    ..TCR-transduced T-cells are thus attractive candidates for evaluation in cell transfer therapies of patients with cancer...
  42. ncbi Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma
    Paul F Robbins
    Surgery Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892-7502, USA
    J Immunol 169:6036-47. 2002
    ..These observations provide an impetus to develop strategies directed toward generating HLA class II-restricted tumor-reactive T cells...
  43. ncbi Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:4415-23. 2005
    ..These results strongly support the idea that redirection of normal T cell specificity by TCR gene transfer can have potential applications in tumor adoptive immunotherapy...
  44. ncbi Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes
    Amelia Grover
    Surgery Branch and Dermatology Branch, National Cancer Institute/NIH, 10 Center Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 12:5801-8. 2006
    ....
  45. ncbi T-cell receptor gene therapy of established tumors in a murine melanoma model
    John D Abad
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 31:1-6. 2008
    ..This model may be a powerful tool for evaluating future TCR gene transfer-based strategies...
  46. ncbi Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines
    R Zakut
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892
    Cancer Res 53:5-8. 1993
    ....
  47. ncbi CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production
    G Zeng
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 98:3964-9. 2001
    ....
  48. ncbi Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen
    C E Touloukian
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892
    Cancer Res 61:8100-4. 2001
    ..polypeptide-specific CD8+ T cells capable of recognizing P.polypeptide expressing human tumor cell lines in an HLA-A*0201-restricted fashion. Thus, P.polypeptide may be valuable in the creation of novel therapeutic anticancer vaccines...
  49. ncbi Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1
    Christopher E Touloukian
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 170:1579-85. 2003
    ..Thus, the tumor-bearing state reverses, in part, the tolerance of T cells that results from the normal expression of tissue differentiation Ags...
  50. ncbi Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression
    Hung T Khong
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother (1997) 27:184-90. 2004
    ..This paper thus provides evidence for both the effectiveness of the immune destruction of cancer as well as problems associated with antigen-loss tumor escape mechanisms...
  51. ncbi Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 176:7726-35. 2006
    ..004) with the ability of these TILs to mediate tumor regression following adoptive transfer...
  52. ncbi MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte
    M I Nishimura
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 59:6230-8. 1999
    ....
  53. ncbi Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
    R F Wang
    National Cancer Institute, Bethesda, Maryland 20892, USA
    J Exp Med 184:2207-16. 1996
    ..Like other melamona differentiation antigens, TRP-2 was only expressed in melanoma, melanocytes, and retina, but not in other human tissues tested...
  54. ncbi Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase
    J P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:212-20. 2001
    ..1+ tyrosinase+ melanoma cells. These data suggest that tyrosinase:8-17 may be clinically useful for the treatment of patients with melanoma...
  55. ncbi Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells
    D Nagorsen
    Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA
    Gene Ther 10:1754-65. 2003
    ....
  56. ncbi Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity
    K Liu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 167:6356-65. 2001
    ..These tumor-reactive IL-2 transductants may be valuable for in vitro studies and for improved adoptive transfer therapies for patients with metastatic melanoma...
  57. ncbi Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
    Laura A Johnson
    Surgery Branch, Hatfield Clinical Research Center, National Cancer Institute NIH, Bethesda, MD 20892, USA
    Blood 114:535-46. 2009
    ..This trial was registered at www.ClinicalTrials.gov as NCI-07-C-0174 and NCI-07-C-0175...
  58. ncbi Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination
    Daniel J Powell
    Surgery Branch, National Cancer Institutes of Health, Bethesda, MD 20892, USA
    J Immunother (1997) 27:36-47. 2004
    ....
  59. ncbi IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells
    Christopher A Klebanoff
    Howard Hughes Medical Institute National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA
    Proc Natl Acad Sci U S A 101:1969-74. 2004
    ..These results provide several avenues for improving adoptive immunotherapy of cancer in patients...
  60. ncbi A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 33:648-58. 2010
    ..The methodology described here could be readily applied for engineering CD8+ T cells with antitumor specificity for human adoptive immunotherapy...
  61. ncbi Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    Rajeev K Shrimali
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 70:6171-80. 2010
    ..These studies provide a rationale for the exploration of combining antiangiogenic agents with ACT for the treatment of patients with cancer...
  62. ncbi A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas
    William R Burns
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 70:3027-33. 2010
    ..This may represent a novel means to treat the majority of patients with advanced melanoma, most notably those unable to receive current ACT therapies...
  63. ncbi TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 174:5215-23. 2005
    ....
  64. ncbi Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma
    Juhua Zhou
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 173:7622-9. 2004
    ..A similar analysis may also be useful for monitoring autoimmune responses...
  65. ncbi Cancer regression in patients after transfer of genetically engineered lymphocytes
    Richard A Morgan
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    Science 314:126-9. 2006
    ..This study suggests the therapeutic potential of genetically engineered cells for the biologic therapy of cancer...
  66. ncbi Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma
    Kimberly R Lindsey
    Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 12:2526-37. 2006
    ....
  67. ncbi Bcl-2 overexpression enhances tumor-specific T-cell survival
    Jehad Charo
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:2001-8. 2005
    ..Our data suggest that adoptive immunotherapy approaches to the treatment of cancer patients may be enhanced using Bcl-2-modified tumor-reactive T cells...
  68. ncbi Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine
    Cary Hsu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:7226-34. 2005
    ..In the setting of adoptive cell transfer, IL-15-transduced lymphocytes may prolong lymphocyte survival in vivo and could potentially enhance antitumor activity...
  69. ncbi Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes
    Simone Seiter
    Department of Transfusion Medicine, Center for Cancer Research, National Cancer Institute, Building 10, Room 2B42, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Immunother (1997) 25:252-63. 2002
    ..These data provide direct enumeration of MART-1/MelanA and gp100/pMel17 reactivity ex vivo and in vitro in the context of HLA-A*0201...
  70. ncbi The use of melanosomal proteins in the immunotherapy of melanoma
    Y Kawakami
    Surgery Branch, National Institutes of Health, Bethesda, MD 20892 1502, USA
    J Immunother 21:237-46. 1998
    ..These studies may demonstrate the feasibility of using melanosomal proteins for the immunotherapy of patients with melanoma...
  71. ncbi Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1
    T S Weiser
    Thoracic Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:151-61. 2001
    ..Although the mechanisms have not been fully defined, sequential DAC-DP treatment may be a novel strategy to augment antitumor immunity in cancer patients...
  72. ncbi Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2)
    M R Parkhurst
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:4895-901. 1998
    ..These results suggest that TRP2 may be useful for the development of murine tumor immunotherapy models and for the treatment of melanoma patients who are diverse in HLA expression...
  73. ncbi Short-term kinetics of tumor antigen expression in response to vaccination
    G A Ohnmacht
    Surgery Branch, Department of Transfusion Medicine, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 167:1809-20. 2001
    ..This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy...
  74. ncbi Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100
    Y Zhai
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 20:15-25. 1997
    ..These results may suggest that immunization with heterologous tumor antigen, rather than self, may be more effective as an immunotherapeutic reagent in designing antigen-specific cancer vaccines...
  75. ncbi Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1
    Y Kawakami
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol Methods 202:13-25. 1997
    ..These reagents may be useful for biological studies on melanocytes and melanoma cells as well as for the development and monitoring of immunotherapy for patients with melanoma...
  76. ncbi Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
    Peter Attia
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1201, USA
    J Immunother (1997) 28:582-92. 2005
    ..Administration of Denileukin Diftitox does not appear to eliminate regulatory T lymphocytes or cause regression of metastatic melanoma...
  77. ncbi IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells
    Mojgan Ahmadzadeh
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 30:294-302. 2007
    ....
  78. ncbi CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent
    Luca Gattinoni
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Mark O Hatfield Clinical Research Center, 10 Center Drive, Room 3 5750, Bethesda, MD 20892, USA
    Blood 108:3818-23. 2006
    ..These results indicated that CD8(+) CLTA-4(-/-) T-cell-mediated autoimmunity and tumor immunity required CD4(+) T cells in which the function was dysregulated by the absence of CTLA-4-mediated negative costimulation...
  79. ncbi Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma
    Steven Yeh
    National Eye Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20814, USA
    Ophthalmology 116:981-989.e1. 2009
    ..To describe the ophthalmic and systemic autoimmune findings after successful adoptive cell transfer of ex vivo expanded, autologous tumor-reactive tumor-infiltrating lymphocytes (TIL) for metastatic melanoma...
  80. ncbi A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity
    Yangbing Zhao
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 183:5563-74. 2009
    ..More importantly, PBLs expressing this new version of the 4D5 CAR could not only efficiently lyse the autologous fresh tumor digests, but they could strongly suppress tumor growth in a xenogenic mouse model...
  81. ncbi Laser scanning cytometry evaluation of MART-1, gp100, and HLA-A2 expression in melanoma metastases
    S Mocellin
    Department of Transfusion Medicine, Clinical Center, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother 24:447-58. 2001
    ..5 expressed significantly less gp100. Thus, laser scanning cytometry yields detailed information on protein expression in individual cells and represents a new tool for dissecting the immune response in the tumor microenvironment...
  82. ncbi Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition
    T Z Zaks
    Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Immunol 162:3273-9. 1999
    ....
  83. ncbi Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors
    T Z Zaks
    Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1502, USA
    Cancer Res 58:4902-8. 1998
    ..However, the CTLs failed to react with HER-2/neu+ tumor cells. Further studies are needed to determine whether and how HER-2 might serve as an antigen for tumor immunotherapy...
  84. ncbi T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product
    Jianping Huang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 172:6057-64. 2004
    ....
  85. ncbi Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    Kimberly E Beck
    Surgery Branch and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA
    J Clin Oncol 24:2283-9. 2006
    ..0065 for MM and P = .0016 for RCC). CONCLUSION: CTLA4 seems to be a significant component of tolerance to tumor and in protection against immune mediated enterocolitis and these phenomena are significantly associated in cancer patients...
  86. ncbi Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes
    Laura A Johnson
    Surgery Branch, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunol 177:6548-59. 2006
    ..We propose that inducing expression of this highly avid TCR in patient PBMC has the potential to induce tumor regression, as an "off-the-shelf" reagent for allogeneic melanoma patient gene therapy...
  87. ncbi Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR
    Cyrille J Cohen
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 175:5799-808. 2005
    ..These results suggest that lymphocytes genetically engineered to express anti-p53 TCR may be of value for the adoptive immunotherapy of patients with a variety of common malignancies...
  88. ncbi Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells
    Shicheng Yang
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Immunother 31:830-9. 2008
    ..Compared with gamma-retroviral vectors, the TCR transgene could be preferentially expressed on a less-differentiated cell population...
  89. ncbi Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression
    Jennifer A Wargo
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Immunol Immunother 58:383-94. 2009
    ..These results have relevance for TCR-based gene therapies targeting common epithelial malignancies...
  90. ncbi Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities
    John P Riley
    Surgery Branch, National Cancer Institute, National Institutes of Health, Room 2B42, Building 10, 9000 Rockville Pike, Bethesda, MD 20892-1502, USA
    J Immunol Methods 276:103-19. 2003
    ..These results suggest that the use of peptide mixtures may facilitate the identification of new tumor-associated antigens through the application of reverse immunology...
  91. ncbi Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3-3940, 10 Center Dr MSC 1201, Bethesda MD 20892-1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..CONCLUSION: Lymphodepleting chemotherapy followed by the transfer of highly avid antitumor lymphocytes can mediate significant tumor regression in heavily pretreated patients with IL-2 refractory metastatic melanoma...
  92. ncbi Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen
    Hung T Khong
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA
    J Immunother (1997) 27:472-7. 2004
    ..This result raises questions about the use of synthetic peptides derived from NY-ESO-1 as a sole form of immunization...
  93. ncbi Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions
    F M Marincola
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 1502, USA
    J Immunother Emphasis Tumor Immunol 19:192-205. 1996
    ....
  94. ncbi Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells
    R F Wang
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Exp Med 189:1659-68. 1999
    ..This represents the first demonstration that a fusion protein resulting from a chromosomal rearrangement in tumor cells serves as an immune target recognized by CD4(+) T cells...
  95. ncbi Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A
    J N Cormier
    Surgery Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer J Sci Am 3:37-44. 1997
    ....
  96. ncbi Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA
    J Immunother (1997) 29:398-406. 2006
    ..Major histocompatibility complex class II TCR-transduced CD4 T cells provides an alternative source of tumor antigen-specific T cells for adoptive immunotherapy of cancer patients...
  97. ncbi Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling
    Yangbing Zhao
    Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1201, USA
    Cancer Res 67:2425-9. 2007
    ..The genetic manipulation of HSCs has broad implications for ACT of cancer...
  98. ncbi Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene
    Cary Hsu
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 109:5168-77. 2007
    ..It does not appear that the retroviral vector integration sites played a role in the continuous growth of this cell clone, but this remains under investigation...
  99. ncbi Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2
    Bianca Heemskerk
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Hum Gene Ther 19:496-510. 2008
    ..In this study, insertion of the IL-2 gene into antitumor TILs increased their ability to survive after IL-2 withdrawal in vitro but did not increase their in vivo persistence or clinical effectiveness...
  100. ncbi Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Immunother 31:189-98. 2008
    ....
  101. ncbi Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
    Claudia Wrzesinski
    Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
    J Immunother 33:1-7. 2010
    ..Thus, increased intensity lymphodepletion triggers enhanced tumor treatment efficacy and the benefits of high-dose total body irradiation must be titrated against its risks...